Phase 2 N=51 Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome
Tobacco Abstinence Syndrome
Primary: Episodic Memory — 11.6; 10.0 number of words recalled
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=119 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 — 10; 3 Participants — p=0.0745
N/A N=21 Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers
Nicotine Dependence
Primary: Change in Post-Resist Craving — 6; 3.6 units on a scale
Phase 4 N=379 Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.
Rheumatoid Arthritis
Primary: Remission According to DAS28-CRP at Week 16 — 69; 72; 61; 25 Participants
N/A N=20 Clinical Trial of Dipyridamole in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale
Phase 4 N=27 An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Changes From Baseline in the Standard Deviation (SD) of 24-hour Blood Glucose Values — -7.51; -13.04; -11.76; -15.24 mg/dL
Phase 3 N=218 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Acute Undifferentiated Leukemia · Childhood T Acute Lymphoblastic Leukemia
Primary: Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2) — 35.82 percentage probability
Phase 2 N=3 Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
Scalp Psoriasis
Primary: Number of Participants With HPA Axis Suppression — 0; 2 Participants
Phase 1 N=6 Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol
Contraception · Menopause
Primary: Mass Balance of Total Radioactivity in Urine — 68.97 Cumulative percent excreted (%)
N/A N=100 In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia
Chronic Sinusitis
Primary: Patency Rate — 38; 33 sinus sides — p=0.0391
Phase 3 N=162 A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 2 — 5.52; 5.53; -1.41; -1.22 units on a scale
Phase 4 N=8 Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis
Primary: Diffusion and Myelin Fraction Water Changes on Magnetic Resonance Imaging (MRI) — -2.06 percent Change
Phase 3 N=506 A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) — -1.00; -0.89; -0.20 Percentage A1C — p=<0.001
Phase 2 N=224 Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis Lesions (AKs) — 12.7; 5.1; 26.8; 0.0 percentage of participants — p=0.18
Phase 3 N=148 A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Clostridium Difficile-associated Diarrhea (CDAD)
Primary: Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days — 77.6; 70.5 percentage of participants